Zehna Therapeutics is an early stage biotech company focused on developing novel small molecules targeting specific gut microbial pathways to treat chronic disease
OUR SCIENCE
Zehna Therapeutics is developing non-bacteriocidal inhibitors of selected gut microbial pathways clinically and mechanistically linked with chronic metabolic diseases. Our lead compounds inhibit the gut microbial enzyme CutC, preventing the conversion of dietary choline to trimethylamine (TMA) and subsequently to trimethylamine N-oxide (TMAO) within the host.
High systemic levels of TMAO have been linked to accelerated development of both cardiovascular and chronic kidney disease, as demonstrated in large-scale clinical cohort studies. Chronic Kidney Disease is our lead indication.
OUR LEADERSHIP
OUR BOARD OF DIRECTORS
CLINICAL ADVISORS
LATEST NEWS
Cleveland Clinic, Tufts University Research Ties Gut Microbial TMAO Pathway to Chronic Kidney Disease
New findings from Cleveland Clinic and Tufts University researchers show high blood levels of TMAO (trimethylamine N-oxide) predicts future risk of developing chronic kidney disease over time.
Read More →A Novel, Small Molecule Inhibitor of Gut Microbial CutC Slows the Loss of Kidney Function in a Rat Model of CKD
Presented at ASN by Jerry Buysse, Robert Matunas, Camilla V. Simpson. Zehna Therapeutics Inc., San Francisco, CA, United States
Read More →Targeting Microbes to Treat Heart Disease
Deep in the recesses of the gut, they wait, ready to devour whatever comes their way. The microbes that live in the human intestines are not picky; their food is our food. But what we decide to eat — whether a greasy cheeseburger or a beet salad — determines not just the microbes’ health but our own.
Read More →Publications
Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulo…
Basic Sciences
May 2020
Development Of A Gut Microbe–Targeted Nonlethal Therapeutic To Inhibit Thrombosis Potential
Nature Medicine
September 2018